MYD88 and neoplasm: Advanced imaging modalities such as multiparametric MRI, together with CSF analysis for circulating tumor DNA, molecular profiling (e.g., MYD88, CD79B), and proteomic mass-spectrometry approaches, hold promise for achieving greater diagnostic precision and more accurate compartmental differentiation between CNS and systemic lymphoma [4,41,42,43].